Arrowhead Press Release Archive
July 30, 2009
Arrowhead Senior Advisors Featured in Nature and Nature Medicine Articles
July 16, 2009
Arrowhead Increases Ownership in
Carbon Nanotube-based Electronics Films Subsidiary Unidym Inc. to 70%
July 10, 2009
Arrowhead Announces Private Placement of $2 Million
July 10, 2009
Arrowhead announces CFO Transition
June 23, 2009
Arrowhead Subsidiary Calando Pharmaceuticals Enters into License Agreement with Cerulean Pharma Inc.
May 15, 2009
Arrowhead Reports Second Quarter Fiscal 2009 Financial Results
March 6, 2009
Arrowhead to Transfer to The NASDAQ Capital Market
February 18, 2009
Arrowhead CEO Comments on Recent Nasdaq Letter
February 13, 2009
Arrowhead Receives Notification of Minimum Stockholders’ Equity Non-Compliance from the Nasdaq Stock Market
February 9, 2009
Arrowhead Reports First Quarter Fiscal 2009 Financial Results
January 26, 2009
Arrowhead's Majority Owned Subsidary, Unidym, Inc. Consolidates Operations
December 15, 2008
Arrowhead Reports Fourth Quarter and Full Year 2008 Financial Results
December 8, 2008
Calando Pharmaceuticals Publishes New Results of siRNA Delivery
Using Its RONDEL(TM) Technology in Sepsis
December 3, 2008
Arrowhead Raises $5.4 Million into Two Subsidiaries; Initiatives Strengthen Balance Sheet for 2009
November 19, 2008
Arrowhead CEO Provides Update on Tego Biosciences Corporation
November 17, 2008
Arrowhead Research Corporation Retains The Piacente Group, Inc. as Strategic Investor Relations Consulting Firm
November 12, 2008
Arrowhead CEO Provides Update on Nanotope, Inc.
November 4, 2008
Arrowhead CEO Provides Update on Majority Owned Subsidiary Unidym, Inc.
November 3, 2008
Calando Pharmaceuticals to Present at 19th Annual
Oppenheimer Healthcare Conference on November 4, 2008
October 31, 2008
Arrowhead Research Corporation to Present at
AeA Classic Financial Conference November 4 and 5, 2008
October 28, 2008
Arrowhead CEO Provides Update on Wholly Owned Subsidiary Agonn Systems, Inc.
October 23, 2008
Calando Pharmaceuticals Announces Completion of IT-101 Phase 1 Clinical Study
October 21, 2008
Arrowhead CEO Provides Update on Majority Owned Subsidiary Calando Pharmaceuticals Inc.
October 16, 2008
Unidym Announces a Demonstration by Samsung Electronics of
the First Color Carbon Nanotube-Based Electrophoretic Display
October 14, 2008
Arrowhead CEO Updates Stockholders
October 7, 2008
Calando Patent Issued for Active Ingredient of Lead siRNA Drug Candidate, CALAA-01
October 2, 2008
Unidym Licenses Technology for Semiconductor Applications
September 15, 2008
Calando Pharmaceuticals Announces Next siRNA Therapeutic Candidate for Oncology
September 11, 2008
CALANDO PHARMACEUTICALS PHASE II CLINICAL STUDY OPENS TO PATIENT ENROLLMENT
September 9, 2008
ARROWHEAD COMPLETES PREVIOUSLY ANNOUNCED REGISTERED DIRECT OFFERING RAISES A TOTAL OF $6.9 MILLION TO FUND OPERATIONS
August 12, 2008
UNIDYM ENTERS INTO SECOND JOINT DEVELOPMENT AGREEMENT WITH SAMSUNG ELECTRONICS TO INTEGRATE CARBON NANOTUBES INTO DISPLAY DEVICES
July 21, 2008
ALNYLAM GRANTS NEW INTERFERX(TM) INTELLECTUAL PROPERTY LICENCE TO CALANDO FOR DEVELOPMENT AND COMMERCIALIZATION OF RNAi THEARPEUTICS
July 9, 2008
ARROWHEAD FORMS NEW SUBSIDIARY TO COMMERCIALIZE ENERGY STORAGE DEVICES
June 17, 2008
ARROWHEAD SUBSIDIARY, UNIDYM, RECEIVES STRATEGIC INVESTMENT FROM ENTEGRIS
June 12, 2008
CALANDO PHARMACEUTICALS COLLABORATES WITH CITY OF HOPE TO INITIATE INVESTIGATOR SPONSORED CLINICAL TRIAL USING IT-101 IN LYMPHOMA PATIENTS
June 5, 2008
BATTELLE AND UNIDYM INC. FORM AN ALLIANCE FOCUSED ON THE USE OF CARBON NANOTUBES IN COMPOSITES
June 2, 2008
CALANDO PHARMACEUTICALS DOSES FIRST PATIENT IN siRNA PHASE I CLINICALTRIAL
May 20, 2008
UNIDYM DEMONSTRATES FIRST FULL COLOR ACTIVE MATRIX LCD USING A CARBON NANOTUBE-BASED TRANSPARENT ELECTRODE
May 19, 2008
UNIDYM'S CTO DR. PAUL DRZAIC NAMED NEW PRESIDENT OF THE SOCIETY FOR INFORMATION DISPLAY
May 16, 2008
UNIDYM TO EXHIBIT AND PRESENT AT LEADING DISPLAY CONFERENCE
May 15, 2008
ARROWHEAD EXPANDS EXECUTIVE TEAM TO BROADEN TECHNICAL AND OPERATIONAL EXPERTISE
May 13, 2008
CALANDO GRANTED BROAD PATENT RIGHTS TO RNAi TECHNOLOGY IN CHINA
May 6, 2008
ARROWHEAD SELLS SUBSIDIARY AONEX TECHNOLOGIES TO AMBERWAVE SYSTEMS FOR UP TO $7.95 MILLION PLUS ROYALTY
April 24, 2008
ARROWHEAD NANOBIOTECHNOLOGY SUBISIDARIES, CALANDO PHARMACEUTICALS AND INSERT THERAPEUTICS COMPLETE MERGER
April 22, 2008
UNIDYM INC. ANNOUNCES THE FIRST FLIGHT OF AN AIRCRAFT USING CARBON NANOTUBES FOR INCREASED FUSELAGE STRENGTH
April 21, 2008
Calando Receives FDA Approval for Phase I Clinical Trial Using a Targeted siRNA Nanoparticle Therapeutic
April 17, 2008
Insert Therapeutics to Initiate a Multinational Phase II Clinical Trial of Lead Drug Candidate IT-101 in Ovarian Cancer
March 18, 2008
UNIDYM INC. SPINS OFF ENSYSCE BIOSCIENCES INC. TO PURSUE MEDICAL THERAPEUTIC APPLICATIONS OF CARBON NANOTUBES
March 14, 2008
ARROWHEAD CEO PRESENTS 2008 OBJECTIVES
March 13, 2008
ARROWHEAD SUBSIDIARY, CALANDO PHARMACEUTICALS, SUBMITS IND FOR CLINICAL TRIAL WITH TARGETED, NANO-DELIVERED RNAi THERAPEUTIC FOR CANCER
March 12, 2008
ARROWHEAD RESEARCH SUBSIDIARY, UNIDYM, ENTERS INTO DEVELOPMENT AGREEMENT WITH NIPPON KAYAKU TO INTEGRATE CARBON NANOTUBES INTO THIN FILM SOLAR CELLS
March 5, 2008
ARROWHEAD CEO TO PRESENT OBJECTIVES FOR 2008 VIA WEBCAST FOLLOWING ANNUAL MEETING OF SHAREHOLDERS
February 28, 2008
ARROWHEAD STREAMLINES BUSINESS MODEL OF NANOBIOTECH SUBS, CALANDO PHARMACEUTICALS AND INSERT THERAPEUTICS
February 12, 2008
Arrowhead Announces the Appointment of Dr. Chad Mirkin
February 11, 2008
Arrowhead Research Subsidiary, Unidym, Ramps Up Manufacturing to Meet Carbon Nanotube Demand
January 28, 2008
Arrowhead Announces the Appointment of Dr. Mauro Ferrari to its New Board of Advisors
January 22, 2008
Arrowhead CEO Invited to Give Keynote Presentation at Rice Alliance Nanotechnology Venture Forum